Type A - Ryan Specialty Holdings, Inc. (RYAN) 20261102 Stock Analysis

📅 Ryan Specialty Key Upcoming Events

• November 10, 2026 Quarterly Dividend Ex-Date (Confirmed)
  • Description: Ryan Specialty’s upcoming ex-dividend date provides the next scheduled shareholder-income milestone. The regular annualized dividend is $0.52 per share, representing a modest yield relative to the company’s growth-oriented investment profile.
• February 11, 2027 Q4 and FY2026 Earnings Release (Estimated)
  • Description: The estimated date follows Ryan Specialty’s historical February reporting pattern. The company has not officially confirmed this date, and the schedule may change. Investors will focus on full-year organic revenue growth, the effect of softer specialty insurance pricing, adjusted EBITDAC margins, acquisition integration, and the initial FY2027 outlook.

🏢 Step 1: Ryan Specialty Company Overview & Business Model

Q1-A1. What is Ryan Specialty?

• Company Name (Ticker): Ryan Specialty Holdings, Inc. (RYAN)
• Sector: Financials
• Exchange: NYSE
• Founded: January 2010
• Listing Date: July 22, 2021
• Fiscal Year End: December
• Headquarters: United States, Chicago
• CEO: Timothy W. Turner
• Market Cap: $11.03B
• Shares Outstanding: 251.58M
• Current Stock Price: $43.84
• Annual Dividend Yield: 1.19%
• Ex-dividend Date: November 10, 2026 (ET)
• As-of: November 02, 2026 (ET)

Q1-A2. How Does Ryan Specialty Make Money?

• Specialty Insurance Brokerage Commissions: Ryan Specialty earns commissions and fees by connecting retail insurance brokers with specialty insurance carriers capable of underwriting complex, unusual, or difficult-to-place risks.
• Delegated Underwriting Services: Through managing general agents and managing general underwriters, the company designs insurance programs, evaluates risks, and administers policies on behalf of carriers in exchange for contractual fees and commissions.
• Capital-Light Intermediation: Ryan Specialty generally does not retain the insurance underwriting risks borne by its carrier partners. Consequently, its economic performance depends primarily on placement volume, commission rates, professional expertise, operating efficiency, and relationships rather than insurance claims experience.
• Customer Proposition: Retail brokers gain access to specialized insurance markets and underwriting expertise, while carriers benefit from established distribution networks and outsourced underwriting capabilities.
• Revenue Economics: Commissions generally follow insurance premium volumes and placement activity. Rising insured exposures, client retention, specialty market penetration, and acquisitions support growth, while falling premium rates can reduce revenue even when policy volumes remain stable.

Q1-A3. Ryan Specialty’s Revenue Segments & Core Income Sources

• Wholesale Brokerage — 51.7% of Net Commissions and Fees:
  • During the first nine months of 2026, Wholesale Brokerage generated approximately $1.27B, increasing 4.6% year over year.
  • This remains Ryan Specialty’s largest business, distributing complex specialty property, casualty, professional liability, and other insurance products through RT Specialty.
  • Its competitive strength comes from broker relationships, carrier access, placement expertise, and the ability to source coverage for difficult risks.
• Underwriting Management — 36.0% of Net Commissions and Fees:
  • Revenue reached approximately $886.65M during the first nine months of 2026, increasing 17.3% year over year.
  • This business includes delegated underwriting arrangements, managing general agencies, and specialized insurance programs.
  • It is the company’s fastest-growing major business and increasingly important to earnings diversification.
• Binding Authority — 12.3% of Net Commissions and Fees:
  • Revenue reached approximately $303.18M during the first nine months of 2026, increasing 6.0% year over year.
  • Binding Authority processes relatively standardized specialty risks using delegated insurer authority and established distribution channels.
  • Higher transaction volumes and workflow efficiency support scalability.
• Revenue Mix Interpretation: These percentages use the $2.46B nine-month net commissions and fees denominator and exclude fiduciary investment income. Underwriting Management’s increasing contribution provides diversification from traditional wholesale brokerage activity.

Q1-A4. Who Are Ryan Specialty’s Competitors?

• Direct Wholesale Brokerage Competitors:
  • Amwins is a major competitor across specialty wholesale brokerage, binding authority, and underwriting services.
  • CRC Group competes in specialty insurance placement and complex commercial risk distribution.
  • Other regional wholesalers and specialist managing general agents compete for brokers, insurance carrier capacity, and experienced producers.
• Broader Insurance Intermediary Competitors:
  • Arthur J. Gallagher, Brown & Brown, Aon, and Marsh McLennan operate within the broader insurance distribution ecosystem, although their business mixes and direct competitive overlap vary.
  • Large retail brokers may expand internal specialty capabilities or establish competing delegated underwriting programs.
• Competitive Advantages:
  • Ryan Specialty combines wholesale distribution, specialized underwriting talent, carrier relationships, and a growing portfolio of managing underwriters.
  • Its scale helps match difficult risks with appropriate insurance capacity, creating operational advantages over smaller intermediaries.
• Competitive Limitations:
  • Its services are relationship-intensive, and experienced producers remain important assets.
  • Carrier relationships are not exclusive across every line, and customers can redirect business toward competitors if service quality, pricing, or placement performance deteriorates.
• Industry Position: Ryan Specialty is among the leading specialty insurance intermediaries, with particularly meaningful positions in U.S. wholesale distribution and delegated underwriting management.

Q1-A5. Ryan Specialty Key Events: Past 12 Months

• February 12, 2026 Q4 and FY2025 Earnings Release
  • Description: The company reported its FY2025 operating performance following a year of strong acquisition-supported growth. The results established a challenging comparison base for 2026, particularly in underwriting management.
• April 30, 2026 Q1 2026 Earnings Release
  • Description: Ryan Specialty continued expanding revenue during the first quarter, supported by its specialty insurance distribution franchise and acquired operations. Investors increasingly focused on the distinction between reported growth and organic growth.
• May 26, 2026 Share Repurchase Program Expansion
  • Description: Ryan Specialty announced a $300.00M increase to its share repurchase authorization, supporting capital returns alongside acquisitions and dividend payments.
• June 24, 2026 RT Specialty Leadership Succession Announcement
  • Description: The company announced a planned leadership transition within its principal wholesale brokerage operations. Execution matters because broker relationships and producer retention are important sources of competitive advantage.
• July 30, 2026 Q2 2026 Earnings Release
  • Description: Revenue reached $916.60M, growing 7.2% year over year, while organic growth was 6.7%. The results demonstrated positive underlying growth despite a more difficult specialty insurance pricing environment.
• October 29, 2026 Q3 2026 Earnings Release
  • Description: Revenue rose 4.7% to $789.96M, organic revenue increased 4.0%, and adjusted EBITDAC rose 3.8% to $244.45M. Management maintained its mid-single-digit FY2026 organic growth outlook but guided to a modest decline in full-year adjusted EBITDAC margin, underscoring rising compensation pressure and slower organic momentum.

Q1-A6. Step 1 Key Takeaways

• Step 1 Summary: Ryan Specialty is a scaled, capital-light specialty insurance intermediary with substantial distribution and delegated underwriting capabilities. Its long-term advantages remain meaningful, but slowing organic growth and margin pressure have become central investment considerations.

🏰 Step 2: Ryan Specialty’s Economic Moat, Growth & Capital Allocation

Q2-A1. Does Ryan Specialty Have a Durable Economic Moat?

• Specialized Expertise: Complex insurance placements require detailed knowledge of carrier underwriting appetite, specialized coverage terms, and evolving risk exposures. Accumulated institutional expertise creates barriers that are difficult for smaller entrants to replicate quickly.
• Distribution Relationships: Ryan Specialty benefits from extensive networks of retail brokers and specialty insurance carriers. These relationships provide access to business opportunities and underwriting capacity that newer competitors may struggle to establish.
• Switching Costs: Broker relationships are not contractually permanent, but established workflows, successful placement histories, and specialized underwriting capabilities create practical switching friction.
• Pricing Power: Specialty expertise supports commission economics, but Ryan Specialty does not fully control insurance premiums or commission rates. Carrier competition and softer insurance pricing can restrict revenue growth.
• Profitability Defense: TTM ROIC of approximately 11.49% exceeds the estimated 6.81% WACC, indicating positive economic returns despite acquisition-related investment and substantial intangible assets.
• Moat Assessment: The franchise possesses a durable expertise-and-relationships moat, although it is not protected by exclusive technology or irreplaceable network effects.

Q2-A2. Is Ryan Specialty’s Growth Sustainable?

• Industry Structure and Outlook: Demand for specialty insurance services is supported by increasingly complex commercial risks, excess-and-surplus insurance distribution, and insurers’ willingness to outsource specialized underwriting capabilities. Premium pricing remains cyclical, however, and the industry’s revenue opportunity does not grow at a constant rate.
• Growth Sustainability: Ryan Specialty has opportunities to expand through organic placements, delegated underwriting programs, and acquisitions. Nevertheless, Q3 2026 organic growth of 4.0%, versus 15.0% a year earlier, demonstrates meaningful deceleration.
• Downside Scenarios:
  • 1 Specialty Pricing Softens: Falling insurance premium rates outweigh new client wins and exposure growth, reducing commission revenue and operating leverage.
  • 2 Carrier Capacity Contracts: Insurers withdraw underwriting capacity from selected products or reduce delegated authority, limiting placements and program expansion.
  • 3 Acquisition Returns Disappoint: Integration expenses, producer departures, or weaker-than-expected acquired revenue reduce earnings growth and cash generation.

Q2-A3. How Does Ryan Specialty Allocate Capital & Return Cash?

• Acquisitions: Ryan Specialty has historically used acquisitions to broaden specialty underwriting capabilities and expand distribution relationships. This strategy can generate attractive returns but introduces integration, goodwill, leverage, and execution risks.
• Share Repurchases: The May 2026 $300.00M authorization increase expanded capital-return flexibility. During Q3 2026, Ryan Specialty repurchased approximately 3.50M Class A shares for $150.00M.
• Dividends: The annualized dividend of $0.52 per share provides a modest income component, but dividend income is not the dominant investment thesis.
• Debt Management: The company must balance acquisitions and buybacks against elevated financial leverage. Its TTM debt-to-EBITDA ratio of approximately 4.06x makes disciplined capital allocation particularly important.
• Capital Allocation Assessment: Management has demonstrated a willingness to return capital, but meaningful leverage and acquisition requirements constrain flexibility.

Q2-A4. Step 2 Key Takeaways

• Scoring Rationale:
  • Economic Moat (8/10): Extensive broker relationships, underwriting expertise, and specialized market access support durable competitive advantages, with some pricing sensitivity.
  • Growth Sustainability (6/8): Structural specialty insurance demand and underwriting management expansion support growth, but organic revenue momentum has slowed materially.
  • Capital Allocation (5/7): Dividends and repurchases are positive, while acquisition dependence and leverage reduce financial flexibility.
• 📊 Step 2 Score: 19/25 pts (Economic Moat 8/10 + Growth Sustainability 6/8 + Capital Allocation 5/7)
• Step 2 Summary: Ryan Specialty possesses a valuable competitive franchise and credible long-term growth opportunities. The principal constraints are insurance pricing cyclicality, slowing organic growth, and acquisition-related leverage.

💰 Step 3: Is Ryan Specialty Profitable? Financial Health Analysis

Q3-A1. Ryan Specialty’s Growth & Profitability Trends

• Revenue Growth Remains Positive but Slower: Revenue increased from approximately $2.46B in FY2024 to $3.00B in FY2025, representing growth of approximately 22.0% on the net-commission revenue presentation. TTM revenue through September 2026 reached approximately $3.20B, with growth slowing to approximately 10.1%.
• Q3 Operating Profit Improved Faster Than Revenue: Q3 2026 revenue increased 4.7% to $789.96M, while operating income increased 27.1% to $140.83M from $110.79M. Operating margin consequently increased from approximately 14.7% to 17.8%.
• Net Income and EPS Improved: Q3 consolidated net income increased 40.6% to $88.05M. Diluted GAAP EPS increased from $0.20 to $0.29, while adjusted diluted EPS rose from $0.47 to $0.51.
• Adjusted Operating Leverage Is Less Favorable: Adjusted EBITDAC margin declined from 31.2% to 30.9% in Q3. Although GAAP operating margin improved, compensation expenses and business mix constrained underlying adjusted profitability.
• Free Cash Flow Has Moderated: TTM FCF was approximately $499.12M, compared with FY2025 FCF of $572.70M. The TTM FCF margin of 15.6% was below FY2025’s 19.1%, indicating that cash-flow conversion has weakened despite continuing profitability.
• Earnings Interpretation: Strong GAAP profit growth contrasts with slower adjusted operating earnings growth. Acquisition accounting, noncontrolling interests, and expense adjustments make a single GAAP EPS observation insufficient to judge normalized earning power.

Q3-A2. How Profitable Is Ryan Specialty? (Margins & ROIC)

• Return on Invested Capital: TTM ROIC is approximately 11.49%, compared with an estimated WACC of 6.81%, producing a positive spread of approximately 4.68 percentage points.
• Return on Equity: ROE is approximately 25.15%, although leverage and the company’s equity structure increase this measure and limit its usefulness as a standalone indicator.
• Operating Profitability: TTM operating income is approximately $632.68M on $3.20B of reported revenue, equivalent to an operating margin of approximately 19.8%.
• Adjusted Profitability: Q3 adjusted EBITDAC margin of 30.9% reflects the attractive economics of specialty insurance intermediation, but its decline from 31.2% indicates pressure on incremental margins.
• Cost of Capital Considerations: The estimated WACC assumes relatively stable financing conditions and a capital-light operating structure. Higher interest rates, rising debt costs, or lower organic growth could narrow the positive spread.
• Competitive Comparison: Ryan Specialty’s profitability reflects substantial specialty distribution expertise, although direct comparisons with underwriting insurers or diversified brokers require differences in revenue recognition and acquisition accounting to be considered.

Q3-A3. What Drives Ryan Specialty’s Returns? (ROIC Breakdown)

• Selected Efficiency Indicators: Organic Revenue Growth Rate, Adjusted EBITDAC Margin, and Free Cash Flow Conversion are the most relevant indicators because Ryan Specialty primarily monetizes specialized insurance distribution and delegated underwriting services rather than physical assets.
  • Organic Revenue Growth Rate: Q3 growth slowed to 4.0% from 15.0% a year earlier, while nine-month organic growth declined to 7.3% from 11.4%. Lower premium growth and difficult comparisons have reduced operating momentum.
  • Adjusted EBITDAC Margin: Q3 margin was 30.9%, down 0.3 percentage points year over year. Nine-month adjusted margin was 32.1%, compared with 32.4% a year earlier, indicating persistent but moderate profitability pressure.
  • Free Cash Flow Conversion: TTM FCF of $499.12M represents approximately 15.6% of revenue, down from 19.1% for FY2025. The company remains cash-generative, but the lower conversion rate reduces internally funded acquisition and repurchase capacity.
• Operational Driver: Growth depends on producer productivity, retention, insurance placement volumes, underwriting program economics, and compensation expense discipline.
• Return Driver Conclusion: Ryan Specialty’s positive ROIC spread is supported by specialized fee-generating operations, but sustaining attractive returns requires organic growth and acquisition returns to exceed the combined effects of compensation inflation and financing costs.

Q3-A4. Are Ryan Specialty’s Earnings High Quality?

• Cash Generation: TTM operating cash flow is approximately $570.00M, compared with consolidated reported net income substantially below that amount. This reflects strong operating cash generation but also significant noncash expenses and organizational complexity.
• Cash Conversion: Using TTM FCF of $499.12M and standardized consolidated earnings, free cash flow exceeds reported net income. However, acquisition amortization, noncontrolling ownership, and timing differences mean that this relationship should not be interpreted as exceptionally high recurring profitability without adjustment.
• Trend Assessment: FY2023-FY2025 FCF remained positive and increased from approximately $447.43M to $572.70M, but the TTM decline to $499.12M indicates weaker recent conversion.
• Earnings Quality Conclusion: Cash generation supports the economic substance of reported earnings, while acquisition-related adjustments and the complex ownership structure require investors to distinguish GAAP, adjusted, and cash-based earnings.

Q3-A5. Is Ryan Specialty’s Balance Sheet Healthy? (Debt & Leverage)

• Leverage: TTM debt-to-EBITDA is approximately 4.06x, while the company’s debt-to-equity ratio is approximately 4.28x. These measures indicate meaningful acquisition-related financial leverage.
• Liquidity: September 2026 corporate cash and cash equivalents were approximately $168.81M. Fiduciary cash held on behalf of insurance counterparties is not equivalent to unrestricted corporate liquidity.
• Interest Coverage: TTM operating earnings cover interest expense approximately 3.00x, suggesting debt service remains manageable but less flexible than for lightly leveraged insurance intermediaries.
• Net Debt Considerations: Enterprise value of approximately $14.72B versus equity market value of $11.03B indicates a substantial net financing and ownership bridge. Net leverage should be monitored alongside acquisition spending and adjusted operating cash generation.
• Refinancing Risk: The company does not appear dependent on emergency equity financing under current operating conditions, but elevated leverage increases sensitivity to refinancing costs and weaker earnings.
• Financial Health Conclusion: Ryan Specialty retains a profitable, cash-generative operating franchise, although leverage represents a meaningful constraint on aggressive acquisitions and shareholder distributions.

Q3-A6. Step 3 Key Takeaways

• Scoring Rationale:
  • Profitability·Capital Efficiency (8/10): Positive operating margins and an ROIC-WACC spread support meaningful value creation, partially offset by softer adjusted margins.
  • Cash Flow·Profit Quality (6/8): Strong positive FCF and operating cash generation are favorable, but recent conversion has weakened.
  • Financial Soundness·Debt Management (4/7): Debt-to-EBITDA above 4x and moderate interest coverage constrain financial flexibility.
• 📊 Step 3 Score: 18/25 pts (Profitability·Capital Efficiency 8/10 + Cash Flow·Profit Quality 6/8 + Financial Soundness·Debt Management 4/7)
• Step 3 Summary: Ryan Specialty generates attractive operating profits and substantial cash flow, but its leveraged balance sheet and slowing underlying profitability prevent an exceptional financial-strength assessment.

🔎 Step 4: Ryan Specialty Forensic Accounting & Dilution Review

Q4-A1. Does Ryan Specialty Have Accounting Red Flags?

• Revenue recognition: not found
  • Evidence: Revenue primarily consists of insurance placement commissions and service fees recognized under contractual arrangements. The reviewed disclosures do not establish a material revenue-recognition irregularity.
• Cost capitalization: not found
  • Evidence: Acquisitions create substantial goodwill and identifiable intangible assets, but their existence does not independently establish inappropriate capitalization. Amortization and purchase accounting remain important when interpreting adjusted earnings.
• Sharp increase in accounts receivable and inventory: not found
  • Evidence: Inventory is not economically meaningful for this insurance intermediary. Commission receivables and fiduciary balances require monitoring, but reviewed information does not establish a material abnormal buildup relative to business activity.
• Non-recurring adjustment (normalization): discovered
  • Evidence: Ryan Specialty reports adjusted EBITDAC and adjusted EPS alongside GAAP results. Q3 2026 adjusted diluted EPS of $0.51 significantly exceeded GAAP diluted EPS of $0.29, making reconciliation of compensation, amortization, and transaction-related adjustments essential.

Q4-A2. Is Ryan Specialty Overspending? (Capex & Capital Cycle)

• ➖ Not applicable: Ryan Specialty is a capital-light insurance intermediary rather than a capital-intensive manufacturer or commodity producer. Its primary investment risks concern acquisitions, compensation, and organizational integration rather than physical capacity oversupply.

Q4-A3. How Sound Is Ryan Specialty’s Cash Flow?

• Operating Cash Flow: TTM OCF of approximately $570.00M indicates that operations continue generating substantial cash.
• FCF Durability: TTM FCF of approximately $499.12M remains positive despite declining from FY2025’s $572.70M.
• Cash Flow Risk: Acquisition expenditures and share repurchases can exceed internally generated cash in individual periods, making the capital allocation cycle more volatile than underlying operating cash flow.
• Warning Signal Assessment: The observed TTM FCF deterioration deserves monitoring, but positive operating cash generation does not currently establish a persistent financing-dependent operating model.

Q4-A4. Is Ryan Specialty Diluting Shareholders?

• ⏪ Confirmed (Past) Dilution: The standardized total economic share count was approximately 251.58M, up 6.21% year over year. This measure reflects the company’s complex Up-C ownership and unit exchanges; it should not be interpreted automatically as equivalent dilution of existing Class A economic ownership. Q3 repurchases of 3.50M Class A shares offset some potential dilution.
• ⏩ Potential (Future) Dilution & Overhang: Exchangeable LLC interests, employee equity awards, and acquisition-related equity arrangements remain potential share-count and ownership-mix drivers. The precise incremental future issuance amount and timing cannot be established from currently disclosed arrangements without further transaction-specific assumptions.

Q4-A5. Data Integrity Check

• Period: Quarterly Q3 2026, nine-month 2026, FY2025, and TTM September 2026 figures are identified separately ➡ (Pass)
• Definition: GAAP net income and diluted EPS are distinguished from adjusted EBITDAC and adjusted diluted EPS; FCF uses operating cash flow less capital expenditures ➡ (Pass)
• Number of Shares: Class A shares, consolidated economic ownership, and diluted weighted-average shares are distinguished rather than treated as interchangeable ➡ (Pass)
• Unit: Financial amounts are expressed in USD with consistent million/billion conversions; valuation ratios remain dimensionless ➡ (Pass)
• Single Value Confirmation: The latest reported operating figures and standardized valuation measures are applied on their stated bases, with ownership-structure differences explicitly recognized ➡ (Pass)

Q4-A6. Step 4 Key Takeaways

• Scoring Rationale:
  • Accounting anomalies·distortion signals (6/8): No substantiated accounting misconduct is identified, but acquisition adjustments and complex ownership accounting require additional scrutiny.
  • Cash flow warning signals (6/7): Cash generation remains positive and meaningful despite lower recent FCF conversion.
  • Dilution factors (3/5): Repurchases mitigate dilution, but exchangeable interests and share-based compensation complicate per-share analysis.
• 📊 Step 4 Score: 15/20 pts (Accounting anomalies·distortion signals 6/8 + Cash flow warning signals 6/7 + Dilution factors 3/5)
• Step 4 Summary: Ryan Specialty’s operating cash generation supports its reported profitability, although non-GAAP adjustments, acquisition accounting, and ownership-structure changes warrant continued monitoring.

👔 Step 5: Ryan Specialty Management & Shareholder Alignment

Q5-A1. Can You Trust Ryan Specialty’s Management? (Guidance Track Record)

• Leadership Continuity: Timothy Turner became CEO in October 2024 after extensive leadership experience in the company’s wholesale brokerage operations. Founder Patrick G. Ryan remains Executive Chairman.
• Guidance Transparency: Management maintained its FY2026 mid-single-digit organic revenue growth outlook following Q3 results while explicitly acknowledging a modest decline in expected adjusted EBITDAC margin.
• Execution Record: The company’s long-term expansion demonstrates meaningful execution capabilities, particularly in specialty insurance distribution and acquired underwriting operations.
• Guidance Limitations: Q3 2026 organic growth of 4.0%, compared with 15.0% a year earlier, reveals meaningful underlying deceleration despite continued positive adjusted earnings growth.
• Management Assessment: The willingness to communicate margin pressure supports credibility, although the growth outlook should be evaluated against the recent moderation in premium-driven revenue.

Q5-A2. What Are Ryan Specialty Insiders Doing?

• Founder Purchases: Founder and Executive Chairman Patrick G. Ryan purchased 120,000 shares on June 5, 2026, at approximately $32.50 per share, representing an investment of approximately $3.90M.
• Additional Insider Purchases: Director John W. Rogers Jr. purchased 7,500 shares on June 10, 2026. CFO Janice M. Hamilton purchased 6,300 shares on June 3, and executive Mark Stephen Katz purchased 3,215 shares on June 3.
• Insider Selling: Brendan M. Mulshine sold 40,000 shares on September 8, 2026, at approximately $40.51 per share, generating around $1.62M.
• Net Transaction Interpretation: The identified June open-market purchases total approximately 137,015 shares, materially exceeding the identified September sale of 40,000 shares. These transactions represent a positive selected insider accumulation signal, although they are not a complete reconciliation of every Form 4 transaction over the trailing year.
• Management Sentiment: Meaningful founder purchases at substantially lower prices provide a favorable alignment signal, but do not independently establish intrinsic value or guarantee subsequent operating improvements.

Q5-A3. Is Ryan Specialty’s Management Aligned With Shareholders?

• Founder Alignment: Patrick G. Ryan’s continuing leadership and substantial ownership interests support long-term economic alignment with shareholders.
• Governance Structure: The Up-C organization includes public Class A ownership and exchangeable LLC interests, creating a more complex ownership and voting structure than that of a conventional single-class public company.
• Compensation Incentives: Performance-related compensation and equity awards can support retention of valuable insurance professionals, but must be assessed against dilution and cash compensation growth.
• Capital Return Alignment: The expanded repurchase authorization and regular dividend indicate attention to shareholder distributions.
• Governance Assessment: Founder involvement and meaningful insider investment are favorable, while ownership complexity and equity compensation reduce governance simplicity.

Q5-A4. Step 5 Key Takeaways

• Scoring Rationale:
  • Management Trust (4/5): Experienced leadership and transparent margin guidance support credibility despite softer growth.
  • Insider Trends (4/5): Meaningful founder and other insider purchases outweigh the identified large sale, although transactions alone are not conclusive.
  • Governance·Compensation System (3/5): Founder alignment is favorable, but Up-C complexity and incentive-related dilution warrant caution.
• 📊 Step 5 Score: 11/15 pts (Management Trust 4/5 + Insider Trends 4/5 + Governance·Compensation System 3/5)
• Step 5 Summary: Experienced management and substantial insider purchases provide favorable alignment evidence. Governance complexity and compensation-related dilution remain meaningful counterweights.

⛵ Step 6: Ryan Specialty Market Flow & Sentiment

Q6-A1. Analyst Consensus vs Ryan Specialty Guidance

• Company Guidance: Management expects FY2026 organic revenue growth in the mid-single digits and adjusted EBITDAC margin modestly below FY2025.
• Revenue Consensus: Compiled FY2026 revenue estimates are approximately $3.30B, implying roughly 9.6% reported revenue growth over the comparable FY2025 net-commission revenue baseline.
• EPS Consensus: Compiled FY2026 adjusted EPS expectations are approximately $2.19, implying growth of approximately 11.6% on the corresponding adjusted estimate basis.
• Guidance Comparison: The organic guidance and reported revenue consensus measure different growth definitions because acquisitions and other items affect total revenue. They should not be compared as though they were interchangeable.
• Expectation Risk: Q3 organic growth of 4.0% and slightly lower adjusted margins leave limited room for aggressive near-term revisions without improved pricing or business momentum.
• Analyst Sentiment: The analyst distribution has remained broadly stable in recent months, with five Strong Buy, four Buy, nine Hold, and one Sell recommendations among 19 tracked analysts.

Q6-A2. What Is Ryan Specialty’s Short Interest?

• Institutional Ownership: Reported institutional holdings represent approximately 98.99% of the quoted public-share ownership basis. Institutional ownership percentages can overlap with different share-class definitions and should not be added to insider percentages.
• Short Interest: Approximately 13.96M shares were sold short in the latest reported observation.
• Short Interest as Percentage of Float: Approximately 13.37% of the float was short, representing meaningful bearish positioning.
• Days-to-Cover: Approximately 6.64 trading days, indicating that short covering could amplify a favorable earnings or guidance surprise.
• Recent Direction: Short interest increased from approximately 11.98M shares in the preceding monthly observation, suggesting rising skepticism.
• Market Interpretation: The combination of substantial institutional participation and elevated short interest suggests divided expectations rather than uniformly bullish sentiment.

Q6-A3. Step 6 Key Takeaways

• Scoring Rationale:
  • Consensus vs Guidance (2/3): Current earnings expectations appear achievable but remain exposed to slower organic growth and lower margins.
  • Supply·Short Interest (1/2): Elevated short interest and rising bearish positioning offset the potential for positive short-covering momentum.
• 📊 Step 6 Score: 3/5 pts (Consensus vs Guidance 2/3 + Supply·Short Interest 1/2)
• Step 6 Summary: Market expectations reflect continuing earnings growth, but short interest and softer organic performance indicate meaningful skepticism about near-term execution.

🚀 Step 7: Ryan Specialty Catalysts & Price Triggers

Q7-A1. What Could Move Ryan Specialty Stock? (Top 3 Catalysts)

• 1 Recovery in Specialty Insurance Organic Growth
  • Timing: FY2026 Q4 results and subsequent 2027 quarterly disclosures.
  • Success Conditions: Organic revenue growth strengthens toward the upper end of management’s current mid-single-digit framework or improves beyond it, supported by producer productivity and specialty placement volumes.
  • Failure Risk: Continued insurance rate pressure reduces commission revenue faster than volume growth can offset it.
• 2 Stabilization of Adjusted EBITDAC Margins
  • Timing: FY2026 results and the first half of FY2027.
  • Success Conditions: Compensation growth moderates, acquired businesses integrate effectively, and adjusted EBITDAC margin stabilizes or begins improving.
  • Failure Risk: Producer compensation and integration costs continue increasing faster than recurring revenue.
• 3 Stronger Underwriting Management Contribution
  • Timing: Over the next 6-12 months.
  • Success Conditions: Delegated underwriting programs sustain above-company-average growth while maintaining acceptable margins and carrier relationships.
  • Failure Risk: Carrier capacity restrictions, pricing pressure, or integration issues interrupt expansion.

Q7-A2. Ryan Specialty’s Earnings Revision Trend

• Current Earnings Outlook: Compiled FY2026 adjusted EPS estimates are approximately $2.19, with a relatively narrow published range of $2.15-$2.21.
• Recent Operating Evidence: Q3 adjusted EPS rose 8.5% year over year despite organic growth deceleration, suggesting that per-share earnings resilience remains better than the underlying revenue growth trend.
• Revision Direction: A reliable numeric 90-day EPS revision series could not be established. The relatively stable analyst recommendation distribution and maintained organic growth outlook provide no clear evidence of broad upward earnings revisions.
• Revision Assessment: Future estimates are particularly sensitive to specialty premium pricing, compensation expense, and underwriting management growth.

Q7-A3. Step 7 Key Takeaways

• Scoring Rationale:
  • Catalyst (5/7): Organic recovery, margin stabilization, and underwriting management expansion provide credible catalysts, though none is guaranteed.
  • EPS Trend (2/3): Adjusted EPS remains positive and growing, but clear evidence of accelerating estimate revisions is lacking.
• 📊 Step 7 Score: 7/10 pts (Catalyst 5/7 + EPS Trend 2/3)
• Step 7 Summary: Ryan Specialty has several credible operating catalysts, but investors need evidence that slower organic growth and pressure on adjusted margins are stabilizing.

⚖️ Step 8: Is Ryan Specialty Fairly Valued? Valuation Analysis

Q8-A1. Ryan Specialty’s Key Valuation Multiples

• PE Ratio: 55.82x (overvalued) — GAAP earnings produce a high multiple affected by acquisition accounting and the company’s ownership structure.
• PS Ratio: 3.45x (fairly valued) — A meaningful premium is supported by the company’s specialized, asset-light fee revenue, though growth has slowed.
• PB Ratio: 11.81x (overvalued) — The substantial premium to book equity reflects intangible franchise value but provides limited tangible asset support.
• P/TBV Ratio: N/A (not applicable) — Tangible book value is not a meaningful standalone valuation anchor for this acquisition-intensive specialty intermediary.
• P/FCF Ratio: 22.10x (fairly valued) — The approximately 4.5% FCF yield provides some valuation support, although recent conversion has moderated.
• P/OCF Ratio: 19.34x (fairly valued) — Operating cash generation supports the equity value but does not imply a particularly large margin of safety.
• EV/Sales Ratio: 4.60x (fairly valued) — The premium reflects franchise quality and scalable fee income.
• EV/EBITDA Ratio: 16.12x (fairly valued) — Reasonable for a specialized intermediary with recurring relationships, but not especially cheap given growth deceleration.
• EV/EBIT Ratio: 23.26x (overvalued) — Operating earnings do not fully offset the higher enterprise valuation.
• EV/FCF Ratio: 29.48x (overvalued) — The enterprise-value cash-flow multiple highlights the burden of financial leverage.
• Forward PE Ratio: 18.52x (fairly valued) — Forward adjusted earnings provide a more favorable perspective than GAAP trailing EPS, although future growth remains uncertain.
• PEG Ratio: 0.85x (undervalued) — The growth-adjusted multiple appears attractive, but its interpretation depends on the forecast earnings growth definition and sustainability.
• Scoring Rationale: Ryan Specialty’s current valuation appears broadly reasonable using forward adjusted earnings and cash flow, but its elevated GAAP P/E, leverage-adjusted enterprise multiples, and moderating growth prevent a clear absolute discount conclusion.
• 📌 (1) Axis Q8-A1 Score: 0

Q8-A2. Ryan Specialty vs Peers: Valuation Comparison

• Multiple selection based on peer comparison: Forward normalized P/E is appropriate for comparing Ryan Specialty with other profitable insurance intermediaries because it reduces distortions from acquisition amortization and differences in capital expenditure requirements.
• Calculation of peer-to-peer deviation rate: A reliable current arithmetic peer mean could not be established on a fully comparable forecast and adjusted-earnings basis. Therefore, no numerical peer discount or premium is asserted.
  • 🧮 Calculation Formula: ((Ryan Specialty Forward P/E 18.52x - Unverified Comparable Peer Mean) / Unverified Comparable Peer Mean) × 100 = N/A (unverifiable)
• Scoring Rationale: Comparisons with Arthur J. Gallagher, Brown & Brown, and other intermediaries require consistent forward earnings definitions and observation dates. Without those aligned observations, Ryan Specialty’s relative valuation cannot be scored reliably.
• 📌 (2) Axis Q8-A2 Score: 0

Q8-A3. Is Ryan Specialty Cheap or Expensive vs Its History?

• Comparison Indicators: The selected metric is trailing P/FCF because cash generation is economically relevant to the brokerage model. The company has a public trading history beginning in July 2021, but a complete comparable set of quarterly observations or eligible consecutive annual fiscal-year-end valuation observations could not be established. Consequently, a defensible historical minimum, maximum, observation count, and range-position calculation are unavailable.
• Scoring Rationale: The current P/FCF multiple of 22.10x provides an observable valuation anchor, but a verified comparable historical band is necessary to determine its percentile-style range position without mixing incompatible periods or definitions.
• 📌 (3) Axis Q8-A3 Score: 0

Q8-A4. What Growth Is Priced Into Ryan Specialty? (Reverse DCF)

• Implied Growth Rate: 8.9%
  • 1 Methodology: A simplified five-year enterprise-value Reverse DCF estimates the annual growth required in unlevered free cash flow to justify approximately $14.72B of enterprise value.
  • 2 Core assumptions: Starting standardized TTM unlevered FCF is approximately $666.98M, the discount rate is an analyst-assumed 9.0%, the terminal growth rate is 3.0%, and explicit cash flows grow at a constant annual rate over five years. The model uses unlevered rather than equity cash flow to match the enterprise valuation.
• Achievable Growth Rate: 8.0%
  • Basis: An analyst-assumed five-year unlevered FCF growth rate of 8.0% reflects the approximately 8.4% compiled three-year revenue growth outlook, potential operating improvements, and continuing underwriting management expansion, partially offset by slower organic growth and elevated compensation expenses.
• Growth gap and difficulty assessment:
  • 🧮 Formula: Achievable Growth Rate 8.0% - Implied Growth Rate 8.9% = -0.9%p
• Scoring Rationale: The reverse model indicates that the market already discounts growth broadly consistent with a reasonable operating scenario. However, limited headroom exists if insurance pricing weakens further or expense growth prevents margin recovery. Both the implied and achievable figures are conditional on the stated cash-flow, discount-rate, and terminal-value assumptions.
• 📌 (4) Axis Q8-A4 Score: 0

Q8-A4-1. What Growth Hurdle Does the Market Demand From Ryan Specialty? (Reverse DCF Alternative)

• Scoring Rationale: Not applicable — A usable unlevered cash-flow base and coherent enterprise valuation assumptions support the primary Reverse DCF assessment.
• 📌 (4) Axis Q8-A4-1 Score: ➖

Q8-A5. Ryan Specialty’s Hidden Asset & Stake Valuation

• Scoring Rationale: Not applicable — Ryan Specialty’s principal value arises from its consolidated insurance intermediation operations and associated intangible franchise assets; separately realizable investment holdings satisfying the qualifying market-capitalization threshold have not been established.
• 📌 (5) Axis Q8-A5 Score: ➖

Q8-A6. Final Valuation Adjustment

• Scoring Rationale: The company’s Up-C ownership structure and exchangeable economic interests complicate simple share-based valuation, but those effects are already reflected in the selected enterprise-value and per-share accounting considerations. No sufficiently distinct valuation factor warrants an additional adjustment.
• 📌 (6) Axis Q8-A6 Score: 0

Q8-A7. Valuation Adjustment Score Calculation

• Calculation Process:
  • (1) Axis (Key Valuation Indicators): 0 pts (Fairly Valued)
  • (2) Axis (Peer-to-peer deviation rate): 0 pts (N/A vs peers)
  • (3) Axis (Historical Band Position): 0 pts (observed-range position p = N/A; insufficient comparable observations)
  • (4) Axis (Justification for Growth): 0 pts (Achievable growth of 8.0% versus implied growth of 8.9%)
  • (5) Axis (Held assets·Share Valuation): 0 pts (Not applicable)
  • (6) Axis (Final adjustment): 0 pts (No additional material valuation adjustment)
• 📊 Valuation Adjustment Score: A1 (0) + A2 (0) + A3 (0) + A4 (0) + A5 (0) + A6 (0) = 0 pts
• Commentary: Ryan Specialty appears broadly fairly valued on an absolute cash-flow and forward adjusted-earnings basis. Limited historical and directly comparable peer observations prevent stronger relative valuation conclusions, while the reverse cash-flow model indicates that moderate growth expectations are already embedded in the market value.
• Step 8 Summary: The current valuation does not present an obvious bargain, but it is also not clearly excessive relative to sustainable operating cash flow and the company’s specialty insurance franchise.

💀 Step 9: What Are the Risks of Ryan Specialty? Fatal Risks & Pre-Mortem

Q9-A1. What Are the Biggest Risks to Ryan Specialty?

• 1 Continued deterioration in specialty insurance pricing:
  • Cause: Increased insurance carrier capacity and competition can reduce premium rates in selected specialty lines.
  • Impact: Commission revenue may grow more slowly than payroll and other operating expenses, weakening organic growth and adjusted margins.
  • Mitigation/Monitoring Indicators: Monitor quarterly organic revenue growth, premium pricing commentary, insurance placement volumes, and renewal retention.
• 2 Excess leverage and acquisition integration difficulties:
  • Cause: Acquisition-driven expansion has contributed to meaningful financial leverage and intangible asset balances.
  • Impact: Higher interest expense, integration problems, or disappointing acquired business performance could weaken earnings and free cash flow.
  • Mitigation/Monitoring Indicators: Monitor debt-to-EBITDA, interest coverage, acquisition-related cash outflows, and adjusted cash conversion.
• 3 Loss of experienced insurance producers or carrier relationships:
  • Cause: Specialty distribution relies on individual expertise, client relationships, and insurance carrier access.
  • Impact: Producer departures or reduced delegated authority could impair client retention and high-margin specialty business volumes.
  • Mitigation/Monitoring Indicators: Monitor compensation expense ratios, organic growth, major leadership transitions, and underwriting program performance.

Q9-A2. How Sensitive Is Ryan Specialty to the Economy?

• 1 Higher Interest Rates (Negative Impact ⬇): Higher refinancing costs can reduce earnings and constrain acquisition flexibility because the company carries meaningful financial debt.
• 2 Lower Specialty Insurance Premium Rates (Negative Impact ⬇): Lower premiums can directly reduce commission revenue even when the number of policies or insured exposures remains stable.
• 3 Tighter Insurance Distribution Regulation (Negative Impact ⬇): Additional delegated underwriting oversight or licensing requirements could increase compliance costs and reduce operating flexibility.

Q9-A3. Ryan Specialty Pre-Mortem: What Could Go Wrong?

• 1 A prolonged specialty insurance soft market destroys operating leverage: Premium rates decline significantly while compensation and administrative costs remain elevated, causing multiple periods of weak organic growth and shrinking adjusted profitability.
  • Early Warning Signal: Organic revenue growth approaches zero or turns negative while adjusted EBITDAC margin declines for consecutive quarters.
• 2 Acquisition leverage becomes a financial constraint: Weak integration returns and higher refinancing costs reduce cash available for acquisitions, repurchases, and dividends.
  • Early Warning Signal: Debt-to-EBITDA rises materially above its current level while interest coverage and FCF deteriorate.
• 3 Key producer departures undermine the distribution franchise: Experienced brokers or underwriting leaders move to competitors and take valuable customer relationships or specialty market access with them.
  • Early Warning Signal: Major producer departures coincide with declining placement volumes, weakening retention, or lost delegated underwriting agreements.

Q9-A4. Risk Adjustment Score

• Reason for Scoring: Ryan Specialty’s Q3 2026 organic growth fell to 4.0% from 15.0% a year earlier, while adjusted EBITDAC margin narrowed from 31.2% to 30.9%. Management also expects a modest full-year margin decline. These developments demonstrate a continuing, financially observable operating headwind, but the company’s positive growth, substantial cash generation, and established specialty franchise provide important mitigants. The combination of pricing sensitivity and elevated leverage warrants a meaningful risk deduction without suggesting that the core business model is structurally impaired.
• 📊 Risk Adjustment Score: -6 pts
• Step 9 Summary: Slower specialty insurance revenue growth and leverage are the principal downside risks. Ryan Specialty remains profitable and cash-generative, but sustained margin deterioration would weaken its investment profile.

🎯 Step 10: Ryan Specialty Final Verdict: Score & Rating

Q10-A1. Investment Score & Rating

• Investment Score Calculation Formula:
  • Step breakdown: S2 (19) + S3 (18) + S4 (15) + S5 (11) + S6 (3) + S7 (7) = 73 pts
  • Steps 2-7 Sum (73 pts) + Valuation Adjustment (0 pts) + Risk Adjustment (-6 pts) = Investment Score 67 pts
• Investment Score & Rating: 67 pts (B Rating ⭐⭐⭐)
  • Commentary: Ryan Specialty’s specialized distribution network, profitable underwriting services, and meaningful cash generation support an attractive underlying franchise. Slowing organic growth, leverage, and declining adjusted margins temper that strength, while the current valuation offers limited evidence of a compelling discount.

Q10-A2. Should You Buy Ryan Specialty? (Recommendation)

• Recommendation: Hold
  • Commentary: Ryan Specialty combines durable specialty insurance expertise with a growing underwriting management franchise, but its current operating trajectory does not yet establish a decisive improvement in organic growth or profitability. Existing shareholders can reasonably monitor execution, while new investors may benefit from waiting for clearer margin stabilization or a more attractive entry valuation.

Q10-A3. Investment Thesis in One Line

• Ryan Specialty’s specialized insurance distribution network and growing underwriting management operations support long-term earnings growth, but slowing organic revenue, leverage, and compensation pressure limit near-term upside.

Q10-A4. Ryan Specialty’s Price Trend & Key Drivers

• Stock Price Trend Over the Past 12 Months: Declining, Followed by Recovery 📉↗️ — Shares declined approximately 13.8% over the latest 52-week period through October 30, 2026, despite recovering from a 52-week low of $29.28 to $43.84. The 52-week trading range was $29.28-$58.94.
• February 12, 2026 Q4 2025 Earnings Release
  • Description: Results provided an updated view of the company’s acquisition-supported expansion and specialty insurance market conditions.
  • Stock Price Reaction: Positive 📈 — Shares advanced approximately 12.8% by the February 13 close relative to the preceding earnings-session reference.
• April 30, 2026 Q1 2026 Earnings Release
  • Description: The earnings announcement highlighted continuing reported revenue growth and specialty brokerage performance during a changing pricing environment.
  • Stock Price Reaction: Strong Rise 📈 — Shares advanced approximately 11.3% by the May 1 close following the results.
• October 29, 2026 Q3 2026 Earnings Release
  • Description: Ryan Specialty disclosed 4.0% organic growth and a modest decline in adjusted profitability margin while maintaining full-year organic growth guidance.
  • Stock Price Reaction: Modest Rise 📈 — Shares gained approximately 1.3% by the October 30 close, suggesting that the reported slowdown did not prevent a positive immediate market response.

Q10-A5. Action Plan

• Current Price: $43.84
• Buy Zone: $39.00 ($37.00–$41.00)
  • (1) Calculation of Fundamental Value: A conservative entry range below the current price provides additional compensation for slower organic growth, a meaningful debt burden, and uncertainty surrounding adjusted margins. The range corresponds to approximately 16-18x a normalized forward adjusted EPS base near $2.30.
  • (2) Momentum Premium/Discount Application: The recovery from the 52-week low supports avoiding an excessively deep entry discount, but the negative 12-month return and elevated short interest do not justify a material momentum premium.
  • (3) Conclusion: The preferred entry range is $37.00-$41.00, with a midpoint of $39.00. This provides a more attractive balance between franchise quality and the risk of further operating deceleration.
• Price Target: $48.00
• Expected Return: +9.5% (vs. current price)
  • 📍 Selected Valuation Metric: Forward normalized adjusted P/E — an analyst-estimated FY2027 adjusted EPS of $2.40 paired with a 20x target multiple for a 6-12-month valuation horizon.
  • 🧮 Price Target Calculation Formula: FY2027 Normalized Adjusted EPS $2.40 × Target Forward P/E 20x = $48.00
  • ⚓ Valuation Basis and Key Assumptions: The $2.40 FY2027 adjusted EPS estimate is an analyst scenario rather than company guidance or verified consensus. It assumes approximately 9.6% growth from the compiled FY2026 adjusted EPS estimate of $2.19, supported by continued underwriting management expansion and moderate organic revenue growth. A 20x multiple is an analyst judgment reflecting the franchise’s cash-generative economics, positive ROIC spread, and prospective earnings growth, balanced against leverage and margin pressure; an 18-22x range would be plausible under varying operating conditions. Unlike the current-value Reverse DCF, which reflects the market’s existing enterprise value and cash-flow growth expectations, this target uses a future normalized earnings base after prospective operating growth. The principal uncertainties are FY2027 organic growth, adjusted margins, and the comparability of adjusted earnings across periods.
• Conditions and timing for reaching price target: Over the next 6-12 months, the base-case valuation depends on the February 2027 results demonstrating stabilization in organic growth and margins, followed by evidence of sustained underwriting management contribution during subsequent quarterly disclosures.
• Stop Loss: $34.00 ($33.00–$35.00)
• Action trigger upon catalyst achievement:
  • 1 Organic revenue growth rebounds above the current mid-single-digit outlook
    • Description: Stronger placement volumes or improving specialty insurance pricing would reinforce the long-term growth case. Reassess the earnings forecast before increasing exposure. 👉 Consider Buying
  • 2 Adjusted EBITDAC margin stabilizes and begins expanding
    • Description: Improved compensation efficiency would support stronger incremental cash generation and the selected normalized earnings multiple. 👉 Maintain Holdings (Hold)
  • 3 Underwriting Management sustains double-digit revenue growth
    • Description: Continued expansion would strengthen the company’s higher-growth business mix, although acquisition contribution and margins must also be examined. 👉 Maintain Holdings (Hold)
• Action trigger upon risk realization:
  • 1 Organic revenue growth turns negative across consecutive quarters
    • Description: Sustained contraction would challenge the long-term growth assumptions and increase the probability of earnings downgrades. 👉 Reduce Holdings (Sell)
  • 2 Debt leverage rises materially while interest coverage deteriorates
    • Description: A deterioration in financial flexibility would reduce the company’s capacity to fund acquisitions and repurchases safely. 👉 Reduce Holdings (Sell)
  • 3 Adjusted EBITDAC margins decline persistently despite revenue growth
    • Description: Persistent expense pressure would weaken the operating leverage thesis and justify a lower normalized earnings valuation. 👉 Reduce Holdings (Sell)
• Customized Strategy Guide by Investment Preference:
  • Defensive Investors: Prioritize capital preservation and consider new exposure only toward the lower portion of the Buy Zone after evidence of margin stabilization.
  • Neutral Investors: Maintain a measured position while monitoring quarterly organic growth and debt reduction. Add selectively if the price enters the Buy Zone without a deterioration in fundamentals.
  • Aggressive Investors: Consider staged accumulation around the Buy Zone and reassess exposure as earnings catalysts materialize, while respecting the predefined downside boundaries.

🕵️‍♂️ Deep Dive Analysis

Q1: Is Ryan Specialty’s Slowing Organic Growth Its Biggest Weakness?

• Analysis: Ryan Specialty’s Q3 2026 organic revenue growth declined to 4.0% from 15.0% in the prior-year quarter, while nine-month organic growth slowed to 7.3% from 11.4%. The magnitude of this change matters because specialty insurance commissions depend partly on premium pricing, which can change independently of client retention or placement volumes. Management cited a challenging market and maintained mid-single-digit annual organic growth guidance. The company can still grow through acquisitions and underwriting management, but investors should distinguish between durable customer activity and temporary premium-driven revenue expansion. Compensation expenses add another layer of sensitivity: if organic growth weakens further, margins may compress even while absolute revenue continues increasing.
• Judgment: Negative — Organic growth deceleration is the central operating concern because it directly affects earnings expectations and the sustainability of premium valuation multiples.

Q2: Can Ryan Specialty’s 18.52x Forward P/E Be Justified by Its Specialty Insurance Franchise?

• Analysis: Ryan Specialty’s forward P/E of approximately 18.52x is materially lower than its trailing GAAP multiple of 55.82x because expected adjusted earnings differ substantially from reported GAAP earnings. Its specialized distribution network, recurring broker relationships, and delegated underwriting services justify a premium to ordinary low-growth intermediaries. Nevertheless, the company has meaningful leverage, declining adjusted margins, and slowing organic revenue growth. A multiple near 18-20x can be rationalized if adjusted EPS continues growing near a high-single-digit to low-double-digit rate and cash conversion remains strong. Without those conditions, even a seemingly reasonable forward multiple could prove optimistic.
• Judgment: Fairly Valued — The forward valuation appears defensible, but the current operating trajectory does not establish a substantial margin of safety.

Q3: Can Ryan Specialty’s Underwriting Management Business Sustain Its Faster Growth?

• Analysis: Underwriting Management generated approximately $886.65M in net commissions and fees during the first nine months of 2026, up 17.3% year over year and representing 36.0% of the company’s commission revenue. Its growth meaningfully exceeded Wholesale Brokerage’s 4.6%, making it an increasingly important contributor to total business expansion. The delegated underwriting model benefits insurers seeking specialized expertise and variable-cost distribution, but it also relies on carrier capacity and contractual relationships. Acquisitions have contributed to the platform’s expansion, so the sustainability of growth cannot be evaluated solely from reported revenue increases. Future disclosures should distinguish organic program expansion from acquired revenue.
• Judgment: Positive — Underwriting Management is a meaningful structural growth driver, provided integration quality and carrier relationships remain strong.

Q4: How Dangerous Is Ryan Specialty’s Debt Load Above 4x EBITDA?

• Analysis: Ryan Specialty’s reported debt-to-EBITDA ratio is approximately 4.06x, while interest coverage is around 3.00x. These figures reflect a leveraged capital structure that increases financial sensitivity relative to debt-light brokerage peers. However, the company generates substantial positive free cash flow, and its operations generally avoid direct underwriting loss exposure. The principal danger is not necessarily an immediate liquidity crisis but reduced flexibility if operating growth disappoints or acquisition opportunities require additional financing. The company must balance acquisitions, repurchases, dividends, and debt repayment. A prolonged slowdown in organic growth combined with higher refinancing expenses would materially weaken this balance.
• Judgment: Cautious — Leverage is manageable under the current earnings profile but meaningfully increases downside sensitivity.

Q5: Can Ryan Specialty Protect Its Margins During a Softer Insurance Pricing Cycle?

• Analysis: Q3 2026 adjusted EBITDAC margin declined to 30.9% from 31.2%, while the nine-month margin declined to 32.1% from 32.4%. These are moderate changes, but they occurred alongside a significant slowdown in organic growth. Producer compensation and specialized underwriting talent are essential to Ryan Specialty’s business, limiting the speed at which it can reduce expenses without weakening service quality. Higher-margin underwriting management growth may offset some pressure, but this depends on business mix and effective integration. Margin stabilization is therefore a more meaningful near-term indicator than reported revenue growth alone.
• Judgment: Neutral — Margins remain attractive in absolute terms, although the company has not yet demonstrated a sustained recovery in operating leverage.

Q6: Does Ryan Specialty’s Up-C Structure Create Hidden Dilution Risks?

• Analysis: Ryan Specialty’s organizational structure includes publicly traded Class A shares and exchangeable ownership interests in its operating entities. Exchanges can increase the public Class A share count without producing an equivalent increase in total underlying economic claims. Consequently, changes in reported share counts require careful interpretation. Employee compensation, acquisitions, and share repurchases also affect ownership and per-share earnings. The standardized total economic share count increased 6.21% year over year, while Q3 repurchases retired approximately 3.50M Class A shares. Investors should focus on changes in fully diluted economic ownership, net share issuance, and adjusted EPS rather than interpreting individual class conversions as automatic value destruction.
• Judgment: Neutral — The structure creates analytical complexity and potential dilution channels, but share-class exchanges should not be confused with unconditional economic dilution.

Q7: Are Patrick Ryan’s 2026 Insider Purchases a Strong Bullish Signal?

• Analysis: Founder Patrick G. Ryan purchased approximately 120,000 shares for $3.90M in June 2026 at a price near $32.50. Other disclosed insiders also purchased shares around that period, while a notable September sale involved 40,000 shares by Brendan M. Mulshine. Founder purchases using personal capital can provide a more meaningful confidence signal than stock grants or option exercises because they increase direct exposure to market risk. Nevertheless, these purchases occurred at substantially lower prices than the current stock quote, reducing the relevance of the entry valuation for new investors. Insider transactions should reinforce, rather than replace, the assessment of underlying earnings and cash generation.
• Judgment: Positive — Meaningful founder buying supports alignment and confidence, but does not independently demonstrate that the current price is undervalued.

Q8: Will Ryan Specialty Benefit From Continued Growth in Excess-and-Surplus Insurance?

• Analysis: Excess-and-surplus insurance serves difficult or unusual risks that standard insurance carriers may be unwilling or unable to cover on conventional terms. Increasing commercial complexity, litigation exposures, climate-related property risks, and specialized professional liability demand can support long-term activity in this market. Ryan Specialty is positioned to participate through its wholesale brokerage and delegated underwriting capabilities. However, rising E&S premium volumes do not guarantee equivalent commission growth, particularly when premium rates fall or insurance carriers compete aggressively for business. Ryan Specialty’s competitive performance must therefore be measured through organic revenue, placement activity, carrier relationships, and producer productivity.
• Judgment: Positive — Structural demand supports long-term industry opportunities, but premium pricing cycles can materially affect near-term monetization.

Q9: Could Ryan Specialty’s Acquisition Strategy Eventually Reduce Shareholder Returns?

• Analysis: Acquisitions have expanded Ryan Specialty’s product capabilities, geographic reach, and underwriting management operations. This strategy can create value when acquired businesses retain key producers, maintain carrier relationships, and generate returns above financing costs. However, acquisitions also introduce goodwill, intangible amortization, integration expenses, and leverage. If acquired operations underperform, reported revenue growth may conceal weaker underlying capital efficiency. The most useful measures are post-acquisition organic growth, adjusted margins, FCF conversion, debt reduction, and fully diluted earnings growth. Repurchases add value only when executed at attractive prices without compromising financial flexibility.
• Judgment: Cautious — Acquisition-led expansion remains a credible strategy, but disciplined pricing and integration are essential to sustaining per-share value creation.

Q10: What Would Make Ryan Specialty a More Attractive Investment Over the Next 12 Months?

• Analysis: Three developments would materially improve the investment case. First, organic revenue growth should stabilize and recover, indicating that customer activity and specialty distribution demand can offset softer premium pricing. Second, adjusted EBITDAC margins should stop declining as compensation growth moderates and underwriting management gains scale. Third, cash flow should remain strong enough to support debt reduction and shareholder returns without increasing balance sheet risk. On valuation, an entry closer to the $37.00-$41.00 Buy Zone would provide greater downside protection relative to the $48.00 base-case target. Conversely, deteriorating growth, margin pressure, or rising leverage would weaken the case even if the share price declined.
• Judgment: Neutral to Positive — Ryan Specialty has the attributes of a durable specialty insurance compounder, but a more attractive entry valuation or clearer operating acceleration would improve the risk-reward relationship.